The Variation Of IL-10,TGF-β1 In Serum And IL-10 MRNA Expression In PBMC Of Children With Asthma Treated By Specific Immunotherapy

Objective: Asthma is a kind of chronic respiratory passage disease, which threaten the health of people seriously. The tendency of its inception rate is elevated. The main pathological change of asthma is chronic inflammation in respiratory passage and airway hyperreactivity. Now, the chief therapy of this disease is to control the chronic inflammation .Specific immunotherapy is the only etiotropic treatment,which could its cause fatal allergic responseand induced most of people holding a stagger attitude. With the standardization of allergen reductant and normalization of the therapy, the specific immunotherapy has showed up its security and effectivity gradually. The aim of this research is to investigate the possible mechanism of SIT ,by detecting the variation of IL-10,TGF-β₁ in serum and the cytokine of IL-10 mRNA expression in mononuclearcell of children with asthma after 15 weeks and one year later. The other aim is to investigate the security and efficiency of this therapy through observing the clinical therapeutic and the variation of PERMethod: 5 ml venous blood of eighteen asthma children before SIT and fifteen weeks,one years after treatment. Two milliliter of the venous blood were used to extract blood serum and three milliliter of the venous blood is used to extract the mRNA in the mononuclearcell . The double antibody sandwich method was used to detect IL-10,TGF-β₁ in serum. The method of fluorescent reverse transcript tase-polymerase chain reaction was used to detect the IL-10 mRNA expression in mononuclear cell. The control group was twenty healty children with the same age. The method of the test was same to above. The areas of welt in skin test were measured before the therapy and a year after the therapy. The change of PEF were recorded and observe the clinical effects were observed in thirty asthma children with the SIT. The data were dealt with SPSS 13.0 statistical software.Result: 1)The IL-10,TGF-βhas increased after 15 weeks and a year,compard with the beginning .The different has statistical significance. After one year, IL-10 mRNA expression in mononuclear cell is 1.28 multiple than the beginning (p<0. 05) . 2)The content of IL-10,TGF-β₁ is lower than than the control group (p<0. 05) . the IL-10,TGF-β₁ has increased one year later with the therapy but still lower than the control group. 3)The areas of wele in skin test is reduced after one year with SIT .PEF has manifest improve (p<0. 05 ) .4)Part of the patients showed local anaphylaxis,and systemic anaphylaxis response is slighted. Graveness systemic anaphylaxis. is not happened 5)The total effective rate about SIT is 93%,comprared the synchronization(9-12month)before SIT. SIT can palliate the clinical symptom and reduce the symptoms of nose with the asthma children merging allergic coryza.ConcIudsion:1)The deficient of suppress cytokine maybe cause the asthma .2)SIT is a very utility and safety theraphy.3)The possible mechanism of this method lies in regulate T cell produce IL-10,TGF-β. and this induce the immune tolerance and urge T cell nonability.